Xspray Pharma Logo

Xspray Pharma

Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.

XSPRAY | ST

Overview

Corporate Details

ISIN(s):
SE0009973563 (+3 more)
LEI:
549300NGRQCNZ3X4L157
Country:
Sweden
Address:
Scheeles väg 2, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Xspray Pharma is a pharmaceutical company that uses its innovative, patented HyNap technology to develop improved versions of marketed cancer drugs, primarily focusing on protein kinase inhibitors (PKIs). The company's core technology creates amorphous product candidates, which allows it to circumvent the secondary patents of original drugs that are often based on crystalline forms. This strategy enables a unique market entry pathway as soon as the original drug substance patents expire. Xspray Pharma's product candidates, such as its lead product Dasynoc, are designed to retain profile advantages that are beneficial for patients, even compared to generics that replicate the original drug. The technology is reproducible, aiming to reduce development time for future products in its pipeline.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-10 10:00
Board/Management Information
Xspray Pharmas valberedning inför årsstämman 2026
Swedish 44.7 KB
2025-10-10 10:00
Board/Management Information
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026
English 44.5 KB
2025-10-08 02:40
Legal Proceedings Report
Xspray Pharma uppdaterar om FDA-processen för Dasynoc – anmärkningar hos kontra…
Swedish 45.4 KB
2025-10-08 02:40
Legal Proceedings Report
Xspray Pharma provides update on the FDA process for Dasynoc – observations at …
English 45.1 KB
2025-09-30 15:55
Share Issue/Capital Change
Nytt antal aktier och röster i Xspray Pharma efter nyemission
Swedish 42.5 KB
2025-09-30 15:55
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Xspray Pharma after new share issue
English 42.2 KB
2025-09-11 08:00
Share Issue/Capital Change
Xsprays företrädesemission övertecknad –övertilldelningsemission utökad och ful…
Swedish 62.2 KB
2025-09-11 08:00
Share Issue/Capital Change
Xspray’s rights issue oversubscribed – over-allotment issue increased and fully…
English 62.2 KB
2025-08-26 13:10
Share Issue/Capital Change
Första dag för handel i teckningsrätter och BTAs flyttad till 27 augusti
Swedish 57.3 KB
2025-08-26 13:10
Share Issue/Capital Change
First day of trading in subscription rights and BTAs moved to August 27
English 56.6 KB
2025-08-25 16:55
Share Issue/Capital Change
Xspray publishes disclosure document regarding rights issue
English 58.3 KB
2025-08-25 16:55
Share Issue/Capital Change
Xspray offentliggör informationsdokument avseende företrädesemission
Swedish 58.6 KB
2025-08-25 16:45
Share Issue/Capital Change
Xspray receives additional subscription undertakings of SEK 20 million in the o…
English 60.6 KB
2025-08-25 16:45
Share Issue/Capital Change
Xspray erhåller ytterligare teckningsåtaganden om 20 MSEK i den pågående företr…
Swedish 61.1 KB
2025-08-15 08:00
Interim Report
Swedish 1018.3 KB

Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Xspray Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-10 Anders Ekblom Other Buy 168,000 4,998,000.00 SEK
2024-06-04 Ribbskottet AB Anders Bladh Other Buy 1,958 145,655.62 SEK
2024-06-03 Anders Bladh, Ribbskottet Other Buy 3,042 225,077.58 SEK
2024-05-29 Per Andersson Other Buy 51,749 489,545.54 SEK
2024-05-27 Per Andersson Other Sell 9,950 687,545.00 SEK
2024-05-16 Anders Bladh Other Buy 10,000 503,500.00 SEK
2024-05-02 Maris Hartmanis Other Other 2,385 95,400.00 SEK
2024-05-02 Christine Lind Other Other 666 26,640.00 SEK
2024-05-02 Anders Ekblom Other Other 500 20,000.00 SEK
2024-03-05 Robert Molander Other Buy 5,000 20,000.00 USD

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.